BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that advanced breast cancer detection through the use of mammary ductoscopy was a featured topic and reviewed in panel discussions at the 94th Annual American College of Surgeons Clinical Congress in San Francisco, CA. The panel discussed the understanding of the ductal lobular anatomy of the breast and ductal pathologic entities. The Company's current mission is to continue to increase use of its Mammo View(TM) ductoscopy product line in hospitals and breast clinics around the country.
Solos Endoscopy's Mammo View(TM) product line employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the mammary ducts where the majority of breast cancers arise. The Mammo View(TM) system contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Mammo View(TM) has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.
"We're very proud of the work surgeons around the country are conducting to fight breast cancer. The Mammo View(TM) has been developed to be a very easy and powerful tool in the fight against breast cancer and providing early detection for women," stated Bob Segerstein, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2008 PR Newswire.
All rights reserved